Innovation in Drug Research and Development for Prevalent Chronic Diseases Proceedings of a Workshop (2021) / Chapter Skim
Currently Skimming:
Appendix B: Biographical Sketches of Workshop Speakers
Appendix B: Biographical Sketches of Workshop Speakers
Pages 85-96
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 85... ...
In addition to her drug development role, she collaborates to advance technology that transforms the product life cycle for faster and more efficient clinical t rials: integrating innovative tools and methods to disrupt traditional clinical research paradigms, using real-world data to understand the patient journey for better decision making, and incorporating wearables and digital tools into clinical trials. She has been a featured panelist at several conferences, including MassBio Digital Health Impact, BIO Digital 2020, and FierceAI week.
|
From page 86... ...
She is currently a visiting scholar with the American Enterprise Institute, an Aspen Institute Health Innovator Fellow, and a consultant acting as a senior policy advisor to DLA Piper and Charles River Associates. She is a founder and the executive secretary of the Preparedness and Treatment Equity Coalition, an organization focused on identifying metrics and reimbursement pathways to achieve greater equity in health care.
|
From page 87... ...
He has also held senior executive positions in the environmental services, capital management, and venture capital industries. In addition to his professional responsibilities, Mr.
|
From page 88... ...
Ken Ehlert is the chief scientific officer, leading UnitedHealth Group's research and development (R&D) function, an innovation engine intended to positively impact patient health on a global scale.
|
From page 89... ...
She worked for 15 years in the Center for Devices and Radiological Health in guidance document development and as a branch chief overseeing the review of orthopedic devices. She earned an M.S.
|
From page 90... ...
His industry research and development (R&D) experiences include target identification, compound selection, translational biomarker identification, clinical study design and analysis, and external scientific collaborations.
|
From page 91... ...
Before joining U sAgainstAlzheimer's, Mr. Paulsen held executive positions at the United Way and the American Red Cross, working on nationwide challenges in social service and public health.
|
From page 92... ...
Rosen, M.B.A., is an independent consultant and serves on the board of directors of AcelRx Pharmaceuticals, Inc.; Alcobra, Ltd., where he has served as the chair since 2014; ALDEA Pharmaceuticals, Inc.; Entrega, Inc.; Kala Pharmaceuticals, Inc., where he has served as the chair since 2014; and PaxVax, Inc., where he has served as the chair since 2011. From 2004 to 2008, he was the vice president of commercial strategy at Gilead Sciences, Inc., where his responsibilities included strategic marketing, global brand management, health economics, competitive intelligence, market research, and Gilead's overall portfolio and business planning.
|
From page 93... ...
She joined the bio pharmaceutical industry journal BioCentury as a staff writer in 2003, with no background in science or the biopharmaceutical industry, learning about the business and science of developing drugs by interviewing chief executive officers and scientists about their work.
|
From page 94... ...
Her life's work has been to advocate for the acceleration of rigorous multidisciplinary pain research and the translation of research findings into meaningful change for people with chronic pain -- with a special emphasis on pain conditions that are common in women and frequently co-occur. She has been a passionate advocate at the congressional and federal agency levels for bringing about public awareness of the profound impact of chronic pain, the urgent need for an increased federal research investment to address this public health crisis, and the long-overlooked value of including patient perspectives in all aspects of the research continuum.
|
From page 95... ...
Winkfield was an associate professor of radiation oncology at Wake Forest University, the associate director for commu nity outreach and engagement, and the director of the Office of Cancer Health Equity at the Wake Forest Baptist Comprehensive Cancer Center. Prior to joining Wake Forest in August 2016, Dr.
|
From page 96... ...
Dr. Woodahl teaches pharmacokinetics and pharmacogenomics and uses community-based participatory research to address complex and important challenges in conducting precision medicine research with underserved populations.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.